The global Gastro Esophageal Reflux Disease (GERD) Drug market size was valued at US$ 999 million in 2024 and is forecast to a readjusted size of USD 1589 million by 2031 with a CAGR of 6.9% during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Gastro Esophageal Reflux Disease (GERD) Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Gastro Esophageal Reflux Disease (GERD) Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (USD/Pcs), 2020-2031
Global Gastro Esophageal Reflux Disease (GERD) Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (USD/Pcs), 2020-2031
Global Gastro Esophageal Reflux Disease (GERD) Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Pcs), and average selling prices (USD/Pcs), 2020-2031
Global Gastro Esophageal Reflux Disease (GERD) Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Pcs), and ASP (USD/Pcs), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gastro Esophageal Reflux Disease (GERD) Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Gastro Esophageal Reflux Disease (GERD) Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Novartis AG, GlaxoSmithKline, Merck, Medtronic, The Kroger Co., Aros Pharma, AstraZeneca, Plc., Addex Therapeutics, Takeda Pharmaceutical Company Limited, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Gastro Esophageal Reflux Disease (GERD) Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
H2 Receptor Antagonist
Proton Pump Inhibitor (PPi)
Antacids
麻豆原创 segment by Application
Hospital
Clinic
Medical Center
Others
Major players covered
Pfizer
Novartis AG
GlaxoSmithKline
Merck
Medtronic
The Kroger Co.
Aros Pharma
AstraZeneca, Plc.
Addex Therapeutics
Takeda Pharmaceutical Company Limited
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Gastro Esophageal Reflux Disease (GERD) Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Gastro Esophageal Reflux Disease (GERD) Drug, with price, sales quantity, revenue, and global market share of Gastro Esophageal Reflux Disease (GERD) Drug from 2020 to 2025.
Chapter 3, the Gastro Esophageal Reflux Disease (GERD) Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Gastro Esophageal Reflux Disease (GERD) Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Gastro Esophageal Reflux Disease (GERD) Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Gastro Esophageal Reflux Disease (GERD) Drug.
Chapter 14 and 15, to describe Gastro Esophageal Reflux Disease (GERD) Drug sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 H2 Receptor Antagonist
1.3.3 Proton Pump Inhibitor (PPi)
1.3.4 Antacids
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Medical Center
1.4.5 Others
1.5 Global Gastro Esophageal Reflux Disease (GERD) Drug 麻豆原创 Size & Forecast
1.5.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity (2020-2031)
1.5.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Gastro Esophageal Reflux Disease (GERD) Drug Product and Services
2.1.4 Pfizer Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Pfizer Recent Developments/Updates
2.2 Novartis AG
2.2.1 Novartis AG Details
2.2.2 Novartis AG Major Business
2.2.3 Novartis AG Gastro Esophageal Reflux Disease (GERD) Drug Product and Services
2.2.4 Novartis AG Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Novartis AG Recent Developments/Updates
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline Gastro Esophageal Reflux Disease (GERD) Drug Product and Services
2.3.4 GlaxoSmithKline Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 GlaxoSmithKline Recent Developments/Updates
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck Gastro Esophageal Reflux Disease (GERD) Drug Product and Services
2.4.4 Merck Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Merck Recent Developments/Updates
2.5 Medtronic
2.5.1 Medtronic Details
2.5.2 Medtronic Major Business
2.5.3 Medtronic Gastro Esophageal Reflux Disease (GERD) Drug Product and Services
2.5.4 Medtronic Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Medtronic Recent Developments/Updates
2.6 The Kroger Co.
2.6.1 The Kroger Co. Details
2.6.2 The Kroger Co. Major Business
2.6.3 The Kroger Co. Gastro Esophageal Reflux Disease (GERD) Drug Product and Services
2.6.4 The Kroger Co. Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 The Kroger Co. Recent Developments/Updates
2.7 Aros Pharma
2.7.1 Aros Pharma Details
2.7.2 Aros Pharma Major Business
2.7.3 Aros Pharma Gastro Esophageal Reflux Disease (GERD) Drug Product and Services
2.7.4 Aros Pharma Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Aros Pharma Recent Developments/Updates
2.8 AstraZeneca, Plc.
2.8.1 AstraZeneca, Plc. Details
2.8.2 AstraZeneca, Plc. Major Business
2.8.3 AstraZeneca, Plc. Gastro Esophageal Reflux Disease (GERD) Drug Product and Services
2.8.4 AstraZeneca, Plc. Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 AstraZeneca, Plc. Recent Developments/Updates
2.9 Addex Therapeutics
2.9.1 Addex Therapeutics Details
2.9.2 Addex Therapeutics Major Business
2.9.3 Addex Therapeutics Gastro Esophageal Reflux Disease (GERD) Drug Product and Services
2.9.4 Addex Therapeutics Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Addex Therapeutics Recent Developments/Updates
2.10 Takeda Pharmaceutical Company Limited
2.10.1 Takeda Pharmaceutical Company Limited Details
2.10.2 Takeda Pharmaceutical Company Limited Major Business
2.10.3 Takeda Pharmaceutical Company Limited Gastro Esophageal Reflux Disease (GERD) Drug Product and Services
2.10.4 Takeda Pharmaceutical Company Limited Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
3 Competitive Environment: Gastro Esophageal Reflux Disease (GERD) Drug by Manufacturer
3.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Manufacturer (2020-2025)
3.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Revenue by Manufacturer (2020-2025)
3.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Gastro Esophageal Reflux Disease (GERD) Drug by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Gastro Esophageal Reflux Disease (GERD) Drug Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Gastro Esophageal Reflux Disease (GERD) Drug Manufacturer 麻豆原创 Share in 2024
3.5 Gastro Esophageal Reflux Disease (GERD) Drug 麻豆原创: Overall Company Footprint Analysis
3.5.1 Gastro Esophageal Reflux Disease (GERD) Drug 麻豆原创: Region Footprint
3.5.2 Gastro Esophageal Reflux Disease (GERD) Drug 麻豆原创: Company Product Type Footprint
3.5.3 Gastro Esophageal Reflux Disease (GERD) Drug 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Gastro Esophageal Reflux Disease (GERD) Drug 麻豆原创 Size by Region
4.1.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Region (2020-2031)
4.1.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value by Region (2020-2031)
4.1.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Average Price by Region (2020-2031)
4.2 North America Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value (2020-2031)
4.3 Europe Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value (2020-2031)
4.4 Asia-Pacific Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value (2020-2031)
4.5 South America Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value (2020-2031)
4.6 Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Type (2020-2031)
5.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value by Type (2020-2031)
5.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Application (2020-2031)
6.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value by Application (2020-2031)
6.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Average Price by Application (2020-2031)
7 North America
7.1 North America Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Type (2020-2031)
7.2 North America Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Application (2020-2031)
7.3 North America Gastro Esophageal Reflux Disease (GERD) Drug 麻豆原创 Size by Country
7.3.1 North America Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Country (2020-2031)
7.3.2 North America Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Type (2020-2031)
8.2 Europe Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Application (2020-2031)
8.3 Europe Gastro Esophageal Reflux Disease (GERD) Drug 麻豆原创 Size by Country
8.3.1 Europe Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Country (2020-2031)
8.3.2 Europe Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Gastro Esophageal Reflux Disease (GERD) Drug 麻豆原创 Size by Region
9.3.1 Asia-Pacific Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Type (2020-2031)
10.2 South America Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Application (2020-2031)
10.3 South America Gastro Esophageal Reflux Disease (GERD) Drug 麻豆原创 Size by Country
10.3.1 South America Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Country (2020-2031)
10.3.2 South America Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug 麻豆原创 Size by Country
11.3.1 Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Gastro Esophageal Reflux Disease (GERD) Drug 麻豆原创 Drivers
12.2 Gastro Esophageal Reflux Disease (GERD) Drug 麻豆原创 Restraints
12.3 Gastro Esophageal Reflux Disease (GERD) Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Gastro Esophageal Reflux Disease (GERD) Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Gastro Esophageal Reflux Disease (GERD) Drug
13.3 Gastro Esophageal Reflux Disease (GERD) Drug Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Gastro Esophageal Reflux Disease (GERD) Drug Typical Distributors
14.3 Gastro Esophageal Reflux Disease (GERD) Drug Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Pfizer
Novartis AG
GlaxoSmithKline
Merck
Medtronic
The Kroger Co.
Aros Pharma
AstraZeneca, Plc.
Addex Therapeutics
Takeda Pharmaceutical Company Limited
听
听
*If Applicable.
